Abstract
As soon as the diagnosis 'early rheumatoid arthritis (RA)' is made, a disease-modifying antirheumatic drug (DMARD) should be prescribed without delay. Methotrexate in dosages up to 30 mg once weekly is being used more frequently than in the past, also in early RA. Combination therapy with DMARDs is indicated in case of insufficient effect of a single DMARD. Combinations with methotrexate appear to be especially effective, like methotrexate and ciclosporin. A novel effective DMARD is leflunomide. In the near future promising biologicals will probably be applied in clinical daily practice, presumably in combination with conventional DMARDs. New non- steroidal anti-inflammatory drugs (NSAIDs) have been developed that are probably safer than conventional NSAIDs. If the recent finding that glucocorticoids are able to inhibit joint damage in (early) RA will be confirmed, prednisone might be used more often in (early) RA. Bone marrow transplantation in RA is still experimental.
| Translated title of the contribution | Pharmacotherapy of patients with (early) rheumatoid arthritis |
|---|---|
| Original language | Dutch |
| Pages (from-to) | 211-216 |
| Number of pages | 6 |
| Journal | Nederlands Tijdschrift voor Geneeskunde |
| Volume | 144 |
| Issue number | 5 |
| Publication status | Published - 29 Jan 2000 |